Scientific Protocol for the Study of Leukemia and Other Hematologic Diseases Among Clean-up Workers in Ukraine Following the Chernobyl Accident

Leukemia Clinical Trial

Official title: Scientific Protocol for the Study of Leukemia and Other Hematologic Diseases Among Clean-up Workers in Ukraine Following the Chernobyl Accident

Status Completed

Clinical Trial Summary

Leukemia holds a special place in the study of radiation-related cancer because bone marrow is one of the tissues most sensitive to the carcinogenic effect of ionizing radiation, radiogenic leukemia has the shortest latent period among radiation-induced cancers, and its appearance suggests that solid tumors may follow. These same characteristics also contribute to its considerable significance in radiation protection. There are, nevertheless, important gaps in existing knowledge of radiation-induced leukemia, gaps that derive from characteristics of the study of the atomic bombing of Hiroshima and Nagasaki, and from studies of the effects of medical irradiation and studies of nuclear workers, these being the studies that have provided most of the information to date. These gaps include the presumed reduction in risk resulting from dose-fractionation and low dose-rate, and the time-response function in the first five years after exposure.

The primary objective of this study is to investigate leukemia risk as a function of such radiation; it would constitute the largest epidemiologic study conducted to date among working-age males, a group of particular concern in establishing occupational radiation safety standards. In addition, data on cases of multiple myeloma and myelodysplasia identified in the cohort will be collected to test the hypothesis of a dose related association between radiation and increased risk for each of these diseases.

The primary scientific objectives of the proposed study are to test the following hypotheses:

(a) that there is a dose-related increase in risk of leukemia among these liquidators; (b) that the magnitude of any observed risk per unit dose is less than that seen in the atomic bomb survivors, exposed to essentially instantaneous radiation.

Subsidiary objectives include: (a) to investigate the nature of the dose-response relationship among liquidators and to identify modifiers of risk, including time since exposure, age at exposure, etc.; (b) to test the hypothesis that there is a dose-related increased risk of multiple myeloma; (c) to test the hypothesis that there is a dose-related increased risk of myelodysplasial; (d) to collect and store buccal cells from about 2,000 liquidators with a wide range of dose estimates extending to well over 1 Gy for possible use in future molecular studies of their DNA.

Clinical Trial Description

Leukemia holds a special place in the study of radiation-related cancer because bone marrow is one of the tissues most sensitive to the carcinogenic effect of ionizing radiation. Radiogenic leukemia has the shortest latent period among radiation-induced cancers, and its appearance suggests that solid tumors may follow. These same characteristics also contribute to its considerable significance in radiation protection. There are, nevertheless, important gaps in existing knowledge of radiation-induced leukemia, gaps that derive from characteristics of the study of the atomic bombing of Hiroshima and Nagasaki, and from studies of the effects of medical irradiation and studies of nuclear workers; these are the studies that have provided most of the information to date. The gaps include the presumed reduction in risk resulting from dose-fractionation and low dose-rate, as well as the time- response function in the first five years after exposure. The study described herein is intended to fill those gaps.

The Chornobyl accident exposed hundreds of thousands of people to radiation, notably those involved in its cleanup operations. The second phase of a case-control study of ionizing radiation and leukemia is being conducted in a cohort of approximately 100,000 Ukrainian "liquidators" involved in cleanup work following the accident at the Chornobyl Nuclear Power Plant in northern Ukraine which occurred on April 26, 1986. The cohort is restricted to liquidators who first worked around the power plant between 1986 and 1990 and were residents, when first registered in the Chornobyl State Registry, in Kyiv City or in one of five oblasts (major civil divisions) that comprise the study area. This cohort, consisting of males of working age, received mean bone marrow doses of approximately 80-100 milli-gray (mGy) at low to moderate dose rates, with those sent earlier receiving the highest doses. The primary objective of this study is to investigate leukemia risk as a function of such radiation; it constitutes probably the largest epidemiologic study conducted to date among working-age males, a group of particular concern in establishing occupational radiation safety standards.

The primary scientific objectives of the proposed study are to evaluate whether there is a doserelated increase in risk of leukemia among these liquidators, and how it compares with the observed risk per unit dose seen in the atomic bomb survivors, exposed to essentially instantaneous radiation. A secondary objective is to identify any modifiers of risk, including time since exposure, age at exposure, etc.

The field work for the second phase of the study, with an extended case ascertainment for 2001 through 2006 has been complated. As a result of the second phase, a total of75 confirmed cases of leukemia and 12 cases of multiple myeloma have been ascertained. We are currently in the process of database construction, dosimetric calculation for data analyses for leukemia, and manuscript preparation.

The small sub-study on uncertainties associated with human factors is to be started upon SSIRB approval. ;

Related Conditions & MeSH terms

• Hematologic Diseases
• Leukemia

• NCT number: NCT00341016
• Study type: Observational
• Source: National Institutes of Health Clinical Center (CC)
• Status: Completed
• Start date: August 26, 1996
• Completion date: February 12, 2020